Loading…
Prescription Drug Comparative Effectiveness Act of 2002
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
44pct
11d open
vs 5,767 other HR bills in the 107th — cohort avg 49d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2002 · year_end · Medicare/Medicaid
S. 2625 - Medicare Outpatient Prescription Drug Act (Trigger) S. 812, HR 4832 - Medicare Drugs (catastrophic) HR 4954 - Medicare modernization & Prescription Drug Act
Client expense: $131,540 · Firm income: Not reported
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Housing & Urban Development, Dept of (HUD), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), U.S. Trade Representative (USTR)
2002 · year_end · Pharmacy
HR 5272 - Prescription Drugs HR 4832 - Prescription Drugs Comparative Act S. 812, HR 1862 Greater Access to Affordable Pharmaceuitcals Reimportation of Prescription Drugs
Client expense: $131,540 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Federal Communications Commission (FCC), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Housing & Urban Development, Dept of (HUD), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), U.S. Trade Representative (USTR)
2002 · mid_year · Health Issues
S2244 - Prescription Drug Parity Act, HR4833 - Accuracy in Pharmaceuticals Advertising Act, HR3448, S2692 - Reauthorization of the Prescription Drug User Fee Act, S812, HR1862 - Greater Access to Afordable Pharmaceuticals Act, S1052 - Patient Bill of Rights HR4600 - HELP Act Health Issues related to economic stimulus bills (HR3259, HR622, HR30390) HR4954, HR4832, HR490, S2625 - Prescription Drugs Generic Drugs, medical devices, drug reimportation, children's health issues
Client expense: $167,892 · Firm income: Not reported
Government targets: Consumer Product Safety Commission (CPSC), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Housing & Urban Development, Dept of (HUD), Natl Highway Traffic Safety Administration (NHTSA), Office of the Comptroller of the Currency (OCC), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office